Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Heart & blood · 2024

Attruby (acoramidis)

The FDA approved Attruby (acoramidis) on November 22, 2024 to treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis.
Brand name
Attruby
Generic name
acoramidis
FDA approval date
November 22, 2024
Approved use (FDA wording)
To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
Company
Bridgebio Pharma
Application
NDA216540
Dosage form / route
TABLET · ORAL
Boxed warning on label
Not listed
Category on this site
Heart & blood

Indications and usage, from the FDA label

ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.